» Articles » PMID: 16150143

The "lipid Accumulation Product" Performs Better Than the Body Mass Index for Recognizing Cardiovascular Risk: a Population-based Comparison

Overview
Publisher Biomed Central
Date 2005 Sep 10
PMID 16150143
Citations 376
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Body mass index (BMI, kg/m2) may not be the best marker for estimating the risk of obesity-related disease. Consistent with physiologic observations, an alternative index uses waist circumference (WC) and fasting triglycerides (TG) concentration to describe lipid overaccumulation.

Methods: The WC (estimated population minimum 65 cm for men and 58 cm for women) and TG concentration from the third National Health and Nutrition Examination Survey (N = 9,180, statistically weighted to represent 100.05 million US adults) were used to compute a "lipid accumulation product" [LAP = (WC-65) x TG for men and (WC-58) x TG for women] and to describe the population distribution of LAP. LAP and BMI were compared as categorical variables and as log-transformed continuous variables for their ability to identify adverse levels of 11 cardiovascular risk factors.

Results: Nearly half of the represented population was discordant for their quartile assignments to LAP and BMI. When 23.54 million with ordinal LAP quartile > BMI quartile were compared with 25.36 million with ordinal BMI quartile > LAP quartile (regression models adjusted for race-ethnicity and sex) the former had more adverse risk levels than the latter (p < 0.002) for seven lipid variables, uric acid concentration, heart rate, systolic and diastolic blood pressure. Further adjustment for age did not materially alter these comparisons except for blood pressures (p > 0.1). As continuous variables, LAP provided a consistently more adverse beta coefficient (slope) than BMI for nine cardiovascular risk variables (p < 0.01), but not for blood pressures (p > 0.2).

Conclusion: LAP (describing lipid overaccumulation) performed better than BMI (describing weight overaccumulation) for identifying US adults at cardiovascular risk. Compared to BMI, LAP might better predict the incidence of cardiovascular disease, but this hypothesis needs prospective testing.

Citing Articles

The relationship between VAI, LAP, and depression and the mediation role of sleep duration-evidence from NHANES 2005-2020.

Huang Y, Zhao D, Yang Z, Wei C, Qiu X BMC Psychiatry. 2025; 25(1):228.

PMID: 40069662 PMC: 11899296. DOI: 10.1186/s12888-025-06631-8.


Association between metabolic visceral fat score and left ventricular hypertrophy in individuals with type 2 diabetes.

Wang L, Liu S, Ke J, Cao B, Wang D, Zhao Q Diabetol Metab Syndr. 2025; 17(1):81.

PMID: 40050939 PMC: 11884144. DOI: 10.1186/s13098-025-01648-1.


Anthropometric Indices and Metabolic Dysfunction-Associated Fatty Liver Disease in Males and Females Living With Severe Obesity.

Lajeunesse-Trempe F, Dugas S, Maltais-Payette I, Tremblay E, Piche M, Dimitriadis G Can J Gastroenterol Hepatol. 2025; 2025:5545227.

PMID: 39989658 PMC: 11847611. DOI: 10.1155/cjgh/5545227.


Accessible moderate-to-severe obstructive sleep apnea screening tool using multidimensional obesity indicators as compact representations.

Zhu X, Li C, Wang X, Yang Z, Liu Y, Zhao L iScience. 2025; 28(2):111841.

PMID: 39981513 PMC: 11841217. DOI: 10.1016/j.isci.2025.111841.


Assessment of six surrogate insulin resistance indexes for predicting hypertension risk in rural Chinese adults.

Liu G, Cao L, Wen H, Liu M, He X, Wang M Hypertens Res. 2025; .

PMID: 39953234 DOI: 10.1038/s41440-025-02147-6.


References
1.
McGee D . Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005; 15(2):87-97. DOI: 10.1016/j.annepidem.2004.05.012. View

2.
Wagner A, Jorba O, Rigla M, Alonso E, Ordonez-LLanos J, Perez A . LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol. 2002; 39(4):215-20. DOI: 10.1007/s005920200037. View

3.
Lamarche B . Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis. 1998; 9(8):473-81. DOI: 10.1097/00019501-199809080-00002. View

4.
Sniderman A, Lamarche B, Tilley J, Seccombe D, Frohlich J . Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care. 2002; 25(3):579-82. DOI: 10.2337/diacare.25.3.579. View

5.
Austin M, Hokanson J, Edwards K . Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998; 81(4A):7B-12B. DOI: 10.1016/s0002-9149(98)00031-9. View